SubHero Banner

Ravicti® (glycerol phenylbutyrate) – Expanded indication

December 27, 2018 - Horizon Pharma announced the FDA approval of Ravicti (glycerol phenylbutyrate) oral liquid, for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.

Download PDF